Abstract
Background
Trauma is the leading cause of death among children worldwide. The inflammatory response of paediatric patients to multiple injuries can be monitored using serum interleukin-6 (IL-6) levels. This study aimed to assess the value of IL-6 levels in predicting the severity of paediatric trauma and its clinical association with disease activity.
Method
We prospectively tested serum IL-6 levels and evaluated the Paediatric Trauma Score (PTS) and other clinical data among 106 paediatrics trauma patients from January 2022 to May 2023 at the Emergency Department of the Xi’an Children’s Hospital in China. The relationship between IL-6 and trauma severity levels by PTS was analyzed statistically.
Results
IL-6 levels were elevated in 76 (71.70%) of the 106 paediatric patients with trauma. Spearman’s test showed a significant negative linear correlation between IL-6 and PTS (rs = − 0.757, p < 0.001). IL-6 levels were moderate positively correlated with alanine aminotransferase, aspartate aminotransferase, white blood cells, blood lactic acid and interleukin 10 (rs = 0.513, 0.600, 0.503, 0.417, 0.558, p < 0.01). IL-6 levels were positively correlated with hypersensitive C-reactive protein and glucose (rs = 0.377, rs = 0.389, respectively, p < 0.001). IL-6 levels were negatively correlated with fibrinogen and PH (rs = − 0.434, p < 0.001; rs = − 0.382, respectively, p < 0.001). Binary scatter plots further demonstrated higher levels of IL-6 correlated with lower PTS scores.
Conclusion
Serum IL-6 levels significantly increased with increasing severity of paediatric trauma. Serum levels of IL-6 can function as important indicators for predicting disease severity and activity in paediatric trauma patients.
Similar content being viewed by others
Data availability statement
The data presented in this study are available on request from the corresponding author.
References
Collaboration, G.B.o.D.P. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013 findings from the global burden of disease 2013 study. American Medical Association. 2016;170(3):267–287.
Shimony N, Dailey T, Barrow D, Bui A, Noureldine MH, Martínez-Sosa M, Rodriguez LF, Carey CM, Tuite GF, Jallo GI. Pediatric mild head trauma: is outpatient follow-up imaging necessary or beneficial? J Neurosurg Pediatr. 2021;28(1):1–7.
Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8): a028456.
Park S-H, Hwang S-K. Prognostic value of serum levels of s100 calcium-binding protein B, neuron-specific enolase, and interleukin-6 in pediatric patients with traumatic brain injury. World Neurosurg. 2018;118:e534–42.
Sarah R, Abdikarim A, Jeschke MG. 714 IL-6 and soluble IL-6 receptor-two sides of the same coin. J Burn Care Res. 2020;41(Supplement_1):S188–9.
Martin C. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med. 1997;25(11):1813–9.
Qiao Z, et al. Using IL-6 concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis. Eur J Trauma Emerg Surg. 2018;44(5):679–87.
Lecuyer M. Calculated decisions: pediatric trauma score (PTS). Pediatr Emerg Med Pract. 2019;16(5):CD3-4.
Nayduch DA, et al. Comparison of the ability of adult and pediatric trauma scores to predict pediatric outcome following major trauma. J Trauma. 1991;31(4):452–8.
Tepas J. The pediatric trauma score as a predictor of injury severity in the injured child. J Pediatr Surg. 1987;22(1):14–8.
Saladino R, Lund D, Fleisher G. The spectrum of liver and spleen injuries in children: failure of the pediatric trauma score and clinical signs to predict isolated injuries. Ann Emerg Med. 1991;20(6):636–40.
Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(S1):S34–45.
Wang X, et al. Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol. 2019;11(2): a028548.
Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3–4):249–84.
Kang S, et al. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217(5): e20190347.
Kamimura D, et al. IL-6 and inflammatory diseases. In: Yoshimoto T, et al., editors. Cytokine frontiers: regulation of immune responses in health and disease. Tokyo: Springer Japan; 2014. p. 53–78.
Erkus S, Turgut A, Kalenderer O. Alterations in serum IL-6 levels in traumatized pediatric patients: a preliminary study for second hit concept. J Orthop Sci. 2022;27(2):440–7.
Jawa RS, et al. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med. 2011;26(2):73–87.
Öğüş M, et al. The importance of preoperative ALT and AST values in the evaluation of the severity of liver injury in abdominal trauma. Ulus Travma Acil Cerrahi Derg. 1996;2(1):104–6.
Paladino L, et al. Leukocytosis as prognostic indicator of major injury. West J Emerg Med. 2010;11(5):450–5.
Mukama T, et al. Costs of unintentional injuries among children in an urban slum community in Kampala city, Uganda. Int J Inj Contr Saf Promot. 2019;26(2):129–36.
Ooi SZY, et al. Interleukin-6 as a prognostic biomarker of clinical outcomes after traumatic brain injury: a systematic review. Neurosurg Rev. 2022;45(5):3035–54.
Barayan D, et al. Interleukin-6 blockade, a potential adjunct therapy for post-burn hypermetabolism. Faseb j. 2021;35(5): e21596.
Acknowledgements
We thank Mingyue Duan, a researcher from the Department of Clinical Biochemistry, Xi’an Children’s Hospital (The Affiliated Children’s Hospital of Xi’an Jiaotong University), for providing laboratory support.
Funding
This work was supported by the Natural Science Foundation of Shaanxi Province, China (No. 2022JM-606) and the hospital program at the Affiliated Children’s Hospital of Xi’an Jiaotong University, China (No. 2021D04).
Author information
Authors and Affiliations
Contributions
Conceptualization, YM and YS; Data curation, YW, YY, CZ and YS; Formal analysis, QT; Funding acquisition, HZ and YS; Investigation, YY and QT; Software, YW and CZ; Writing—original draft, HZ; Writing—review and editing, YM and YS.
Corresponding author
Ethics declarations
Conflict of interest
Yingge Ma, Yujun Wang, Yanna Yao, Cui Zhang, Qing Tang, Huifang Zhang and Yufei Su declare that they have no conflict of interest. Authors warrant that the article is their original work.
Ethics approval and consent to participate
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. This prospective observational study was initiated after obtaining approval (2021/ V1.1) from Xi’an Children’s Hospital (The Affiliated Children’s Hospital of Xi’an Jiaotong University), where the study was conducted. Informed consent was obtained from all patients for inclusion in the study.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ma, Y., Wang, Y., Yao, Y. et al. High serum interleukin-6 concentration upon admission is predictive of disease severity in paediatric trauma patients. Eur J Trauma Emerg Surg 49, 2287–2294 (2023). https://doi.org/10.1007/s00068-023-02300-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00068-023-02300-1